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quently in the population, if 30% of control subjects manifest this phenomenon.
Three sets of data are presented, each requiring one or the other of these models. In the first, NXCI is found in 53% of invasive ovarian cancer patients compared with 28% of borderline tumor patients and 33% of healthy controls, leading to the conclusion that NXCI predisposes to invasive (but not borderline) ovarian cancer. From these data, we calculate an odds ratio of 2.3 for NXCI-linked ovarian cancer, which would increase the average lifetime risk of about 1.4% to only 2%-3%. We cannot hope to explain familial clustering of ovarian cancer through segregation of such a low penetrance trait.
Nevertheless, family histories of "many" of the ovarian cancer patients with NXCI are remarkable for an excess of breast and ovarian cancers. The number of such cases is not given, but implied is that a rare X-chromosome predisposition allele with high penetrance is associated with familial ovarian cancer. The pedigrees in Fig. 4 (1) are typical of the breast and ovarian cancer syndrome, the majority of which are linked to BRCA1 or BRCA2 (2). In Fig. 5 , Xchromosome allelotype data are presented from three of the families shown in Fig. 4 . In families 8 and 23, the allelotypes are informative for only one affected individual in each family. In family 15, the active X chromosome (which must contain the putative mutant tumor suppressor allele) is different for the two affected family members. The authors interpret this observation as evidence that "NXCI may play a complex role in some hereditary breast and ovarian cancer families," when, in fact, these data provide strong evidence that no Xlinked ovarian cancer predisposition allele is segregating in this family. Additionally, family 15 demonstrates male to male transmission of the putative susceptibility trait, which is incompatible with X linkage.
Finally, nine of 11 ovarian cancer patients with a documented germline mutation of BRCA1 also have NXCI, implying genetic modification of BRCA1 penetrance by an X-chromosome predisposition allele. The data are not presented, although the title of the article suggests otherwise. To be observed in 80% of the BRCA1 carriers with ovarian cancer, a low-penetrance Xchromosome allele must occur at a high frequency in the population studied. The suggestion that "the association of NXCI with germline BRCA1 mutation could in part explain why there are increases in prostate cancer, and colon cancer in addition to breast and ovarian cancer in hereditary breast and ovarian cancer families" is without foundation.
Because we cannot accept that a model involving an X-linked tumor suppressor gene is a viable explanation for the observed association of NXCI with ovarian cancer, other explanations are sought. Postnatal alterations in lymphocyte X-inactivation patterns may result from cancer chemotherapy or aging. As Brown reminds us in an editorial (3), the apparent prevalence of NXCI increases with age, from 10% in neonates to more than 45% in elderly women. Borderline tumors occur at a generally younger age than invasive ovarian cancers, yet Buller et al. did not control for age differences in their analysis. Other possibilities include gene-specific methylation of the androgen receptor as a result of the aging process (4), in which case androgen receptor methylation as a surrogate for NXCI may be inappropriate, and alterations of DNA methylation with storage, which was not controlled for in this study. 
NOTES

RESPONSE
Narod and Boyd (1) have challenged our proposed model of an X-linked tumor suppressor gene invoked to explain the association between nonrandom Xchromosome inactivation and ovarian cancer. They have suggested alternative explanations but focused narrowly on a model wherein the germline mutation of an X-linked tumor suppressor gene contributes to hereditary cancers. We would reiterate from our published article (1) that there are two ways in which an Xlinked tumor suppressor gene contributes to ovarian cancer. The first way provides a subset of sporadic ovarian cancers that are rendered null at the Xlinked tumor suppressor gene locus by virtue of nonrandom X-chromosome inactivation and concomitant loss of the active allele. The calculated odds ratio of 2.3 suggested by Narod and Boyd does not conflict with this model. A second mechanism relates to hereditary ovarian cancer. In this case, a germline mutation of the X-linked tumor suppressor gene associated with nonrandom Xchromosome inactivation does not require loss of heterozygosity. We would accept it as a rare event. Unless the authors' own data (2) have been revised, they and others are unable to explain all cases of hereditary breast and ovarian cancers on the basis of germline BRCA1 and BRCA2 mutations. Thus, the existence of a putative yet elusive BRCA3 gene must be invoked. Where better to hide than on the X chromosome? Until very recently, the X chromosome could be considered a genetically privileged hiding site because of the paucity of markers for high resolution mapping and linkage analysis. Indeed, a putative hereditary prostate cancer susceptibility tumor suppressor gene has only recently been mapped to the X chromosome (3).
Narod and Boyd have clearly misinterpreted the genotype data from Family 15. They state that the active X chromosome is "different for the two family members." This conclusion can only be true if the probands share a common androgen receptor (AR) allelotype. A careful evaluation of Fig. 5 in our article (1) shows that four different allelotypes are expressed between the two probands. Thus, it is impossible to conclude which X chromosome is active. One can only say that the X-linked tumor suppressor gene is not the AR gene itself. Narod and Boyd are correct that male-to-male transmission is incompatible with X linkage. However, the hereditary breast and ovarian cancers in Family 15 are explained by the germline BRCA1 mutation, as shown in the caption to Fig. 5 of our article. Thus, an X-linked tumor suppressor gene is not required for this family. Nonetheless, nonrandom Xchromosome inactivation may still contribute to the penetrance of disease. These data suggest that nonrandom Xchromosome inactivation may be autosomally determined. Hence, our conclusion that nonrandom X-chromosome inactivation is "complex."
Finally, Narod and Boyd were critical of our failure to control for age. Table 1 shows a breakdown of nonrandom X-chromosome inactivation based upon the study group with attention to age at diagnosis (1) . Nonrandom Xchromosome inactivation is independent of age and dependent on health status. Women who develop invasive ovarian cancer are more likely to demonstrate nonrandom X-chromosome inactivation regardless of age at diagnosis. Further investigation of the phenomenon of nonrandom X-chromosome inactivation and its relationship to ovarian cancer and cancer in general are warranted.
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